1

1st Quarter 2019

7 May 2019

Dr. Andreas Eckert

CEO

2

Berlin

Medical Devices (RADIATION THERAPY)

Implantats

Applicators

Devices

Raw materials/

API

Projects/

API

Pharmaceuticals (RADIOPHARMA)

Devices

Globally Positioned

Niche Player in Isotope Market

Industrial Components

(ISOTOPE PRODUCTS)

Products

Services

Trade

Disposal

A strong start in Q01-2019 with a total revenues of 44 Mio. Euro. Calendar year

2018 closed with revenues of 169 Mio. Euro, incl. discontinued operations.

27 Mio. EUR

63%

6 Mio. EUR

15%

10 Mio. EUR

23%

Slides only for illustration – the spoken word shall be binding

800 Employees (Headcounts)

19 Sites Worldwide

3

Results in Q1-2019 (Mio. EUR)

Revenues 43,5

Net Income 5,8

Slides only for illustration – the spoken word shall be binding

43%

46%

9%

2%

EUROPE AMERICA ASIA MIDDLE EAST & AFRICA

2%

Past Years Revenues Outlook

in M

io. E

UR

4

incl. discontinued and continued operations

A total organic growth of 18% in 2018

0,13 1 2 4 6 6 8 10

24

33 31 29

36

42

50 54

71

101

111 116

120 117

127

140 138

145

169

0

20

40

60

80

100

120

140

160

180

1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018

Slides only for illustration – the spoken word shall be binding

Revenues per Segment

Q01-2019 vs. Q01-2018

5 Slides only for illustration – the spoken word shall be binding

Total Revenues of 43,5 Mio. EUR in Q01-2019 vs. 35,7 Mio. EUR in Q01-2018.

And a total organic growth of 19% in Q01-2019.

incl. discontinued and continued operations

0

5

10

15

20

25

30

Isotope Products Radiation Therapy Radiopharma

Q01-2018 22 7 7

Q01-2019 27 6 10

In M

io. E

UR

Revenue Growth all Segments

in Q01-2019, in Mio. EUR

6 Slides only for illustration – the spoken word shall be binding

35,7

+ 4,7 - 0,3

+ 3,4

43,5

0

5

10

15

20

25

30

35

40

45

Revenues Q01-2018 Isotope Products Strahlentherapie Radiopharma Revenues Q01-2019

Isotope Products Revenue

Growth Q01-2019, in Mio. EUR

7 Slides only for illustration – the spoken word shall be binding

High Demand in

Energy Sector 22,4

+ 3,6

+ 1,1

27,2

20

21

22

23

24

25

26

27

28

Revenues Q01-2018 Organic Growth Exchange Rate Effects Revenues Q01-2019

6,6

+ 3,0

+ 0,4

10,0

5

6

7

8

9

10

11

Revenues Q01-2018 Organic Growtth Exchange Rate Effects Revenues Q01-2019

Radiopharma Revenue Growth

Q01-2019, in Mio. EUR

8 Slides only for illustration – the spoken word shall be binding

Pharmaceutical

Radioisotope

6,7

- 0,1 + 0,1

- 0,4

6,4

5

5

5

6

6

6

6

6

7

7

7

Revenues Q01-2018 Organic Growth Exchange Rate Effects M&A and Divesture Revenues Q01-2019

Radiation Therapy Revenue

Growth Q01-2019, in Mio. EUR

9 Slides only for illustration – the spoken word shall be binding

WOMED

lower revenues

in Q01-2019 vs.

Q01-2018

10 Slides only for illustration – the spoken word shall be binding

Q01-2019

Net Income – Distribution and Growth

Net Income in Q01-2019 vs.

Q01-2018 in Mio. EUR

11

Total Net Income of 5,8 Mio. EUR in Q01-2019 vs. 2,3 Mio. in Q01-2018

Slides only for illustration – the spoken word shall be binding

0,0

0,5

1,0

1,5

2,0

2,5

3,0

3,5

Isotope Products Radiation Therapy Radiopharma

Q01-2018 0,9 0,4 1,3

Q01-2019 3,0 0,4 2,4

In M

io. E

UR

Net Income Distribution

by Segment, Q01-2019

12

5,8 Mio. EUR Net Income

Isotope

Products

Radio-

pharma

Radiation

Therapy

3,0 2,4 0,4

Split in Mio. EUR without Holding

Slides only for illustration – the spoken word shall be binding

53%

6%

41%

Isotope Products Radiation Therapy Radiopharma

Revenue Distribution by

Segment, Q01-2019

13 Slides only for illustration – the spoken word shall be binding

43,5 Mio. EUR Revenues

Isotope

Products

Radio-

pharma

Radiation

Therapy

27,2 10,0 6,4

Split in Mio. EUR without Holding

62% 15%

23%

Isotope Products Radiation Therapy Radiopharma

Net Income Growth all Segments

in Q01-2019, in Mio. EUR

14 Slides only for illustration – the spoken word shall be binding

2,3

+ 2,1

- 0,1

+ 1,1

+ 0,3

5,8

0,0

1,0

2,0

3,0

4,0

5,0

6,0

7,0

Net Income Q01-2018 Isotope Products Radiation Therapy Radiopharma Holding Net Income Q01-2019

15 Slides only for illustration – the spoken word shall be binding

Q01-2019

Cashflow and Balance Sheet

Balance Sheet in 2018

in Mio. EUR

16

• Cash at Hand 60 Mio. EUR

• Debt Free

• Equity Ratio 52%

Slides only for illustration – the spoken word shall be binding

Cash 60 Equity 125

Recievables 28 Minority Interests 6

Inventory 30 Loans 0

Intangible Assets 72 Accruals/Provisions 66

Fixed Assets 37 Other Short Term Payables 30

Others 26 Other Long Term Payables 26

Total Activ 253 Total Passiv 253

54,2

7,7

-1,4 -0,7

0,3

60,1

30,0

35,0

40,0

45,0

50,0

55,0

60,0

65,0

Cash at 31.12.2018 CF Operating Activities CF Investing Activities CF Financing Activities Exchange Rate Effects Cash at 31.03.2019

Cashflow in Q01-2019

in Mio. EUR

17 Slides only for illustration – the spoken word shall be binding

EBITDA: 11,6 Mio. EUR

18 Slides only for illustration – the spoken word shall be binding

5 YEAR PERSPECTIVE

19

Mergers and Acquisitions,

Cooperations

• 2014

– Acquisition of Brazilian Isotope Specialist REM

– Accreditation Gallium Generator/ API

– New Projects & Business Activities in Therapy Segment

• 2015 – Sale of US-Seed Business to Theragenics

– Closing of Oxford/ (US)

– Closing of French Sales Accessories Unit

– Lucrative Sales of OPS to IPSEN

• 2016 – Acquisition of Belgian Brachytherapie Unit

– Acquisition of Brazilian Transports Specialist

– Cooperation Contract with CURASIGHT

– FDA-Approval for NETSPOT/ (API of EZAG)

• 2017 – Sale of Zyklotron Business to Alliance Medical

– Acquisition of Gamma-Service Group, Leipzig

• 2018 Acquisition of WOMED

Merger BEBIG S.A. und EZAG AG

Slides only for illustration – the spoken word shall be binding

Profitability (Net Income/ EPS)

of the Past 5 Years

6,8

10,7

9,6

14,7

16,1

1,28 €

2,03 €1,81 €

2,78 €

3,12 €

0,0

2,0

4,0

6,0

8,0

10,0

12,0

14,0

16,0

0,00

0,50

1,00

1,50

2,00

2,50

3,00

3,50

2014 2015 2016 2017 2018

Mio. EUR EUR/Aktie

20 Slides only for illustration – the spoken word shall be binding

„Verdauung“

Industry

& RI

Basis: 5,2 Mio. shares

Planned Profitability in 2019

(Net Income/ EPS)

21 Slides only for illustration – the spoken word shall be binding

Basis: 5,1 Mio. shares

6,8

10,79,6

14,7

16,1

18,1

1,28 €

2,03 € 1,81 €

2,78 €

3,12 €

3,50 €

5,0

7,0

9,0

11,0

13,0

15,0

17,0

19,0

0,50

1,00

1,50

2,00

2,50

3,00

3,50

4,00

2014 2015 2016 2017 2018 2019 Budget

Mio. EUR EUR/Aktie

In 2019, the Group expects an EPS of 3,50 Euro.

Stock and Dividend,

In EUR/Stock

22 Slides only for illustration – the spoken word shall be binding

0,60 0,60 0,600,66

0,8

1,2

0,50

0,60

0,70

0,80

0,90

1,00

1,10

1,20

0

10

20

30

40

50

60

70

80

90

100

2014 2015 2016 2017 2018 2019

Dividende in EUR / Aktie EUR/Aktie

Cashflow Outlook,

in Mio. EUR

23 Slides only for illustration – the spoken word shall be binding

+10 mm EUR for

treasury shares

2014 2015 2016 2017 2018 Q01-2019

Zahlungsmittel 22 31 37 58 54 60

Darlehen 19 16 12 2 0 0

Nettoliquidität 3 15 25 56 54 60

0

10

20

30

40

50

60

0

10

20

30

40

50

60

In M

io. E

UR

Financial Calendar / IR-Contact

IR-Kontakt

Eckert & Ziegler AG

Karolin Riehle

Investor Relations & PR

Robert-Rössle-Str. 10

D-13125 Berlin

Tel. +49 30 94 10 84-138

Fax +49 30 94 10 84-112

karolin.riehle@ezag.de

www.ezag.de

ISIN DE0005659700

Reuters EUZ.DE

24 Slides only for illustration – the spoken word shall be binding

07.05.2019 Quarterly Report I

15.05.2019 Spring Conference in Frankfurt

29.05.2019 Annual General Meeting in Berlin

13.08.2019 Quarterly Report II

12.11.2019 Quarterly Report III

Nov. 2019 German Equity Forum in Frankfurt